Prosecution Insights
Last updated: August 18, 2026

Revvity Health Sciences Inc.

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
2
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (60%)
2
Medium (40%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (40%)
Multi-statute (no §101)3 (60%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
80% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
20% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SHAFQAT, AMY JEANETTE 1 51.7% +55.1%
KAPUSHOC, STEPHEN THOMAS 1 46.7% +53.2%
DAUNER, JOSEPH G 1 56.8% +35.6%
BERTAGNA, ANGELA MARIE 1 44.6% +46.3%
BUCHANAN, BAILEY CHEYENNE 1 47.6% +50.0%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18208140 METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES DAUNER, JOSEPH G 13d
18641547 Systems and Methods for 3D Reconstruction of Anatomical Organs and Inclusions Using Short-Wave Infra SHAFQAT, AMY JEANETTE
18368415 METHODS AND COMPOSITIONS FOR SINGLE-STRANDED NUCLEIC ACID LADDERS BY GUIDED CLEAVAGE KAPUSHOC, STEPHEN THOMAS

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17886126 METHODS AND KITS FOR DEPLETING UNDESIRED NUCLEIC ACIDS BERTAGNA, ANGELA MARIE 9d overdue
18208140 METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES DAUNER, JOSEPH G 13d
18641547 Systems and Methods for 3D Reconstruction of Anatomical Organs and Inclusions Using Short-Wave Infra SHAFQAT, AMY JEANETTE
18368415 METHODS AND COMPOSITIONS FOR SINGLE-STRANDED NUCLEIC ACID LADDERS BY GUIDED CLEAVAGE KAPUSHOC, STEPHEN THOMAS
17556209 DETECTING A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE BUCHANAN, BAILEY CHEYENNE

Top Art Units

Art UnitApps
1682 2
3798 1
1683 1
1681 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18641547 Systems and Methods for 3D Reconstruction of Anatomical Organs and Inclusions Using Short-Wave Infra SHAFQAT, AMY JEANETTE 3798 §102§103 Final Rejection Pending Apr 22, 2024
18368415 METHODS AND COMPOSITIONS FOR SINGLE-STRANDED NUCLEIC ACID LADDERS BY GUIDED CLEAVAGE KAPUSHOC, STEPHEN THOMAS 1683 §103§112 Non-Final OA Pending Sep 14, 2023
18208140 METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES DAUNER, JOSEPH G 1682 §102§103§112 Final Rejection 13d Pending Jun 09, 2023
17886126 METHODS AND KITS FOR DEPLETING UNDESIRED NUCLEIC ACIDS BERTAGNA, ANGELA MARIE 1681 §103 Final Rejection 9d overdue Pending Aug 11, 2022
17556209 DETECTING A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE BUCHANAN, BAILEY CHEYENNE 1682 §103 Non-Final OA Pending Dec 20, 2021

Managing Revvity Health Sciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month